surmount-1 tirzepatide trial obesity without diabetes after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 Gastrointestinal tolerability and weight reduction

8 GLP-1 RAs and DR: What the data show The CDCs Vision and Eye Health Surveillance System estimated that in 2021, there were 9.6 million people (26 percent of those with diabetes) living with diabetic retinopathy in the United States and among them, 1.84 million people (5 percent) living with vision-threatening diabetic retinopathy

[1] [5] It belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists , which work by mimicking the action of a naturally occurring hormone that regulates blood glucose levels

The Wegovy tablet is not a supplement or a simple reformulation

PloS Genet

How Long Until I Notice Results